First-of-its-Kind ADHD pill targets Teens' specific genes
NCT ID NCT02286817
Summary
This early-stage study tested a new oral medicine called NFC-1 in 30 teenagers with ADHD who have specific genetic changes. The main goals were to check if the medicine was safe, how the body processes it, and to look for early signs it might help control ADHD symptoms. Researchers also wanted to see if the teens' specific genetic profiles affected how they responded to the treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Thomas Jefferson University, Clinical Research Unit
Philadelphia, Pennsylvania, 19107, United States
Conditions
Explore the condition pages connected to this study.